Targeted therapy in metastatic bladder cancer: Present status and future directions

6Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

The recommended treatment for metastatic urothelial carcinoma (mUC) patients is platinum-based chemotherapy. Although initial response rates are moderate, the vast majority of patients experience a relapse due to chemoresistance and eventually succumb to their disease. Furthermore, platinum-based chemotherapy is toxic and approximately 30% of mUC patients are unfit for chemotherapy. Thus, there is a clear unmet need for novel, more efficacious treatment options in mUC with a safer toxicity profile. To propel the advancement of novel treatment options, we present a summary of key signaling pathways and molecular mechanisms that are known to be involved in bladder cancer tumorigenesis with a focus on promising candidate druggable molecular targets and innovative targeted therapies currently under clinical investigation. Targetable alterations were mainly described in fibroblast growth factor receptor (FGFR) and epidermal growth factor receptor (ErbB) tyrosine kinase receptor (RTK) families, downstream pathways, and chromatin remodelers, which are major bladder cancer driver genes. Drugs targeting the FGFR family members are emerging as personalized treatment options for selected mUC patients with tumor-specific FGFR alterations. The pan-FGFR inhibitor, erdafitinib, was first-in-class to receive U.S. Food and Drug Administration (FDA) approval in 2019, while inhibitors of ErbB family members have shown less potential. Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that deliver cytotoxic drugs in close proximity to cancer cells by targeting RTKs or other transmembrane proteins. Enfortumab vedotin is the first-in-class ADC that was FDA approved for the treatment of locally advanced or mUC in 2019.

References Powered by Scopus

Pembrolizumab as second-line therapy for advanced urothelial carcinoma

2773Citations
N/AReaders
Get full text

Comprehensive molecular characterization of urothelial bladder carcinoma

2449Citations
N/AReaders
Get full text

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study

2101Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer

13Citations
N/AReaders
Get full text

Cell therapies in bladder cancer management

9Citations
N/AReaders
Get full text

Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Scholtes, M., Akbarzadeh, M., Zwarthoff, E., Boormans, J., Mahmoudi, T., & Zuiverloon, T. (2020, October 2). Targeted therapy in metastatic bladder cancer: Present status and future directions. Applied Sciences (Switzerland). MDPI AG. https://doi.org/10.3390/app10207102

Readers over time

‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

80%

Researcher 1

20%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 2

33%

Medicine and Dentistry 2

33%

Engineering 1

17%

Biochemistry, Genetics and Molecular Bi... 1

17%

Save time finding and organizing research with Mendeley

Sign up for free
0